Drugs / CD19/BCMA CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05263817 | Oct 2021 → Oct 2024 | POEMS syndrome, amyloidosis, autoimmune hemolytic anemia, vasculitis | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05263817 ↗ |
| Modality | Cell therapy | “CD19/BCMA Chimeric Antigen Receptor T Cells” NCT05263817 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT05263817 ↗ |